Document Detail

Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study.
MedLine Citation:
PMID:  17124241     Owner:  NLM     Status:  MEDLINE    
AIM: To evaluate the diurnal intraocular pressure (IOP) control and safety of bimatoprost versus latanoprost in exfoliative glaucoma (XFG).
METHODS: One eye of 129 consecutive patients with XFG (mean (SD) age 66.5 (8.3) years) was included in this prospective, observer-masked, three-centre, crossover comparison. After a 4-6 week medicine-free period patients were randomised to bimatoprost or latanoprost monotherapy for 3 months. Patients were then switched to the opposite treatment for another 3 months. At the end of the washout and the treatment periods diurnal IOP was measured at 0800, 1300, and 1800.
RESULTS: At baseline the IOP (mean (SD)) was 28.0 (4.0), 26.9 (3.6), and 25.9 (3.6) mm Hg, at the three time points, respectively. Both treatments significantly reduced mean diurnal IOP at month 3. Mean diurnal IOP was 26.9 (3.5) mm Hg at baseline, 17.6 (3.3) mm Hg with bimatoprost, and 18.6 (3.6) mm Hg with latanoprost (p<0.0001). Furthermore, lower IOP values were obtained with bimatoprost at all time points (17.9 (3.4), 17.3 (3.3), and 17.6 (3.5) mm Hg, respectively) compared with latanoprost (18.7 (3.6), 18.5 (3.6), and 18.6 (4.1) mm Hg, respectively). The corresponding mean differences (0.8, 1.1, and 1.0 mm Hg, respectively) were all significant (p<0.001 for each comparison). Significantly more patients with XFG obtained a target diurnal IOP <17 mm Hg with bimatoprost than with latanoprost, 55/123 (45%) v 34/123 (28%); (p = 0.001), and significantly fewer patients were non-responders with bimatoprost than with latanoprost (5 v 13, p = 0.021). More patients reported at least one adverse event with bimatoprost than with latanoprost (58 v 41 at 3 months; p = 0.0003).
CONCLUSION: This crossover study suggests that better diurnal IOP control is obtained with bimatoprost than with latanoprost in patients with XFG.
A G P Konstas; G Holló; M Irkec; S Tsironi; I Durukan; M Goldenfeld; S Melamed
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-11-23
Journal Detail:
Title:  The British journal of ophthalmology     Volume:  91     ISSN:  0007-1161     ISO Abbreviation:  Br J Ophthalmol     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-05-18     Completed Date:  2007-07-23     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  0421041     Medline TA:  Br J Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  757-60     Citation Subset:  IM    
Glaucoma Unit, "A" University Department of Ophthalmology, AHEPA Hospital, 1 Kyriakidi Str, Thessaloniki 546 36, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amides / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Circadian Rhythm
Cloprostenol / adverse effects,  analogs & derivatives*,  therapeutic use
Cross-Over Studies
Exfoliation Syndrome / drug therapy*,  physiopathology
Glaucoma / drug therapy*,  physiopathology
Intraocular Pressure / drug effects
Lipids / adverse effects,  therapeutic use*
Middle Aged
Prostaglandins F, Synthetic / adverse effects,  therapeutic use*
Single-Blind Method
Reg. No./Substance:
0/Amides; 0/Antihypertensive Agents; 0/Lipids; 0/Prostaglandins F, Synthetic; 0/bimatoprost; 130209-82-4/latanoprost; 40665-92-7/Cloprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predictions of postoperative visual outcome in subjects with cataract: a preoperative and postoperat...
Next Document:  A novel method for preserving cultured limbal epithelial cells.